生物制药公司Omeros(OMER.US)暴涨超156%,报10.51美元。
消息面上,诺和诺德公布,将斥资高达21亿美元向取得实验性罕见疾病药物的权利。Omeros将获得3.4亿美元的预付款及阶段性付款,其余款项则将与研发及商业里程碑挂钩。该实验药物扎替尼巴特(zaltenibart)正进行用于治疗罕见血液及肾脏疾病的测试。(格隆汇)

本文地址: http://www.jiaotongmi.com/article/19556.html
文章来源:admin
版权声明:除非特别标注,否则均为本站原创文章,转载时请以链接形式注明文章出处。
2025-11-09admin
2025-11-08admin
2025-11-07admin
2025-11-06admin
2025-11-05admin
2025-11-04admin
2025-11-03admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-09-08admin
2025-09-13admin
2025-09-08admin
2025-09-17admin
2025-09-08admin
2025-09-17admin
2025-09-09admin
2025-09-09admin
2025-09-13admin
2025-09-11admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
扫码二维码
获取最新动态
